MODERNA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 145.9 USD | -1.68% |
|
-7.53% | +43.97% |
| 02:21pm | JPMorgan Raises Price Target on Moderna to $96 From $85 | MT |
| 01:09pm | Oppenheimer Raises Price Target on Moderna to $179 From $163 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
148.4
USD
Average target price
144.4
USD
Spread / Average Target
-2.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.97% | 56.87B | |
| +38.31% | 39.72B | |
| -6.58% | 39.27B | |
| -4.42% | 28.73B | |
| +13.46% | 26.21B | |
| -17.32% | 19.79B | |
| +31.82% | 12.28B | |
| +27.39% | 12.23B | |
| -0.38% | 12.12B | |
| -9.41% | 10.84B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna : Says New Study Shows Its COVID-19 Vaccine Maintains Protection Against Key Variants Through Six Months
